Clinical Studies On Level Of β1, β3 Receptor Autoantibody Of Patients With Heart Failure Of Ischemic Cardiomyopathy

Objective:Observe the distribution characteristics of β1 and β3 adrenaline receptor autoantibody(β1-AA and β3-AA) in ischemic cardiomyopathy heart failure of different periods, and to explore the clinical value of β blockers in different antibody distribution characteristics patients.Methods :A total of 60 patients with heart failure as heart failure group,and 50 healthy counter-partners( no heart failure) were chosen as control group.Determine the plasma β1- AA, β3- AA,N-terminal pronatriuretic peptide(NT- proBNP), 24 h ultrasound examination, measurement of left ventricular end-diastolic diameter(LVIDd) and left ventricular ejection fraction(LVEF) of heart failure group in hospital instantly,respectivelye start taking metoprolol,3 months after treatment.To follow-up 1 year after discharge whether its cardiovascular events, including death, malignant arrhythmia, heart failure, etc.).Results :The content of β1- AA/β3- AA in the heart failure group were higher than those in the normal control group(175.23 + 60.22vs160.37 + 38.63, 114.15 + 23.23vs93.35 +11.70). β1- AA/β3- AA value of heart failure group is less than the control group(1.53±0.33 vs1.76 ±0.68, P < 0.05). Patients of Cardiac function grade Ⅳ ischemic cardiomyopathy in acute phase,whose β1- AA/β3- AA lower than patients with cardiacⅢ level(1.51±0.43 vs. 1.55±0.23, P < 0.05).With cardiac function improved, β1 – AA and β3- AA were both decreased, and the ratio is higher in the short term, and then have a downward trend(P < 0.05). β1 – AA / β3- AA of the start of metoprolol in the treatment positively measured with average daily dose of metoprolol succinate sustained release tablets(r=0.86,P <0.05). 1 year after discharge time, compared with patients who were no cardiovascular events, the happening of cardiovascular events in patients with lower lateβ1- AA/β3- AA and average daily dose of metoprolol succinate sustained release tabletsis lower(P < 0. 01);Multivariate Logistic regression analysis using the whole model, the lateβ1- AA/β3- AA, The average daily dose of metoprolol independent prognostic indicator for patients with ischemic cardiomyopathy(P < 0. 01).Conclusions:β1-AA and β3- AA participate in the pathophysiology of ischemic cardiomyopathy heart failureThere was a link between the disorder of β1- AA/β3- AA with ischemic cardiomyopathy heart failure, which can be used to guide clinical treatment of β-blockers to ischemic cardiomyopathy heart failure.